We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-10.55%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$353M
AUM Growth
-$40.7M
Cap. Flow
+$13.6M
Cap. Flow %
3.86%
Top 10 Hldgs %
52.84%
Holding
90
New
8
Increased
24
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$4.3M
2
STOK icon
Stoke Therapeutics
STOK
+$2.54M
3
DNLI icon
Denali Therapeutics
DNLI
+$2.45M
4
INGN icon
Inogen
INGN
+$2.35M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$2.12M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$3.28M
2
AXGN icon
Axogen
AXGN
+$3M
3
ATRC icon
AtriCure
ATRC
+$1.83M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$877K
5
ALKS icon
Alkermes
ALKS
+$864K

Sector Composition

Rank Sector Weight
1 Healthcare 85.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LCTX icon
51
Lineage Cell Therapeutics
LCTX
$278M
$1.13M 0.32%
2,511,374
– –
ALEC icon
52
Alector
ALEC
$199M
$1.12M 0.32%
912,928
– –
FHTX icon
53
Foghorn Therapeutics
FHTX
$360M
$1.11M 0.32%
304,752
+118,035
+63% +$538K
IMTX icon
54
Immatics
IMTX
$1.32B
$1.1M 0.31%
245,000
– –
GPCR icon
55
Structure Therapeutics
GPCR
$3.78B
$1.02M 0.29%
59,000
+23,500
+66% +$576K
YARW
56
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$1.01M 0.29%
+12,722
New +$1.57M
MDWD icon
57
MediWound
MDWD
$185M
$1M 0.28%
64,479
– –
GOSS icon
58
Gossamer Bio
GOSS
$87M
$999K 0.28%
907,854
-501,408
-36% -$580K
BNTX icon
59
BioNTech
BNTX
$23.5B
$956K 0.27%
10,500
+2,000
+24% +$224K
AUTL
60
Autolus Therapeutics
AUTL
$562M
$909K 0.26%
586,667
– –
SAGE
61
DELISTED
Sage Therapeutics
SAGE
$860K 0.24%
108,200
– –
KRRO icon
62
Korro Bio
KRRO
$195M
$820K 0.23%
+47,086
New +$1.4M
IPSC icon
63
Century Therapeutics
IPSC
$361M
$811K 0.23%
1,704,232
– –
LRMR icon
64
Larimar Therapeutics
LRMR
$432M
$799K 0.23%
371,434
– –
PYPD icon
65
PolyPid
PYPD
$92.8M
$789K 0.22%
291,273
– –
TSHA icon
66
Taysha Gene Therapies
TSHA
$1.89B
$726K 0.21%
522,500
– –
BCYC
67
Bicycle Therapeutics
BCYC
$292M
$686K 0.19%
80,799
-40,000
-33% -$471K
NGNE icon
68
Neurogene
NGNE
$712M
$603K 0.17%
51,500
– –
CRDF icon
69
Cardiff Oncology
CRDF
$77.2M
$471K 0.13%
+150,000
New +$593K
ERAS icon
70
Erasca
ERAS
$6.39B
$466K 0.13%
+340,000
New +$584K
IFRX icon
71
InflaRx
IFRX
$271M
$459K 0.13%
+450,000
New +$849K
ACET icon
72
Adicet Bio
ACET
$74.7M
$453K 0.13%
37,500
– –
AQST icon
73
Aquestive Therapeutics
AQST
$494M
$412K 0.12%
142,000
+15,000
+12% +$45.4K
CGEN icon
74
Compugen
CGEN
$228M
$398K 0.11%
272,402
-174,800
-39% -$341K
ADCT icon
75
ADC Therapeutics
ADCT
$144M
$316K 0.09%
224,081
– –
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, DAFNA Capital Management held 90 positions worth $353M, down 10% from $393M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management deployed $13.6M of net new capital in Q1 2025, opening 8 new positions and adding to 24 existing holdings. Its largest new stake was Denali Therapeutics: 127,900 shares worth $1.74M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $3.28M trimmed.

  • DAFNA Capital Management's largest Q1 2025 buy was Denali Therapeutics: 127,900 shares worth $1.74M.
  • DAFNA Capital Management added most to Arcus Biosciences in Q1 2025, an estimated $4.3M increase.
  • DAFNA Capital Management's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $3.28M.
  • DAFNA Capital Management fully exited Centessa Pharmaceuticals in Q1 2025, selling an estimated $795K.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $353M portfolio in Q1 2025.
  • DAFNA Capital Management opened 8 new positions and closed 7 in Q1 2025.
  • DAFNA Capital Management's portfolio value fell 10% quarter-over-quarter to $353M.

Based on DAFNA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.